Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Researchers create new monoclonal antibody treatment effective against both Delta and Omicron

In a new study, researchers conducted surface plasmon resonance experiments using commercially sourced SARS-CoV-2 protein reagents.

6 Jan 2022

Serological antibody response to SARS-CoV-2 infection at a population level

The scientists in this study used pooled convalescent serum to examine the serologic response in a population at risk of infection.

6 Jan 2022

LIVE-AIR trial demonstrates efficacy of Lenzilumab for treatment of COVID patients with decreased oxygen saturation

The LIVE-AIR phase 3 clinical trial is associated with early treatment of hyperinflammatory response with the humanized monoclonal antibody lenzilumab in COVID-19 patients with decreased oxygen saturation. The study results are posted to the medRxiv* preprint server.

6 Jan 2022

Booster dose elicits cross-reactive humoral immunity against SARS-CoV-2 Delta and Omicron variants

Researchers determine the cross-reactivity of the SARS-CoV-2 spike glycoprotein-induced antibodies before and after a third SARS-CoV-2 vaccine dose.

5 Jan 2022

Monoclonal antibody treatment of COVID-19 reduces viral shedding

Researchers aim to understand the potential benefits of mAbs in preventing and treating SARS-CoV-2 infection.

5 Jan 2022

Folic acid-like drug reprograms DNA methylome of aggressive brain tumors

A folic acid-like drug, L-methylfolate, when administered alongside the standard therapy for patients with recurrent glioblastoma, changed aDNA process within their brain tumors, according to results from a phase 1 clinical trial.

5 Jan 2022

Efficacy of COVID-19 convalescent plasma therapy in patients with hematological malignancies and COVID-19

Scientists recently demonstrated the efficacy of COVID-19 convalescent plasma therapy in improving the survival rate among patients with B-cell lymphoid malignancy and COVID-19.

5 Jan 2022

Study finds pan-sarbecovirus nanobodies can enhance development of super-immunity

A new study found that applying pan-sarbecovirus nanobodies shows a strong affinity toward all sarbecovirus clades and neutralized SARS-CoV-2 receptor binding domains

4 Jan 2022

Sino Biological Establishes New Location in Houston, Texas

Sino Biological, Inc. (“Sino Biological” or the “Company”), a biotechnology company listed on ChiNext (SZSE: 301047), provides biological research reagents and related technical contract research services, is pleased to announce its physical geographic expansion, adding a new location in Houston, Texas.

From Sino Biological Inc. 4 Jan 2022

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

Researchers analyzed convalescent sera and sera from immunized individuals to demonstrate the evasion of antibodies by the SARS-CoV-2 Omicron variant.

3 Jan 2022

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

Researchers combine SARS-CoV-2 spike vaccination with single-cell B-cell receptor sequencing technology to discover neutralizing antibody candidates.

3 Jan 2022

TriSb92 as a potential inhibitor against SARS-CoV-2 variants including Omicron

New findings indicate that TriSb92 is a potent inhibitor of SARS-CoV-2 infection targeting a conserved site in the RBD of the spike, which is insensitive for immune escape mutations found in the relevant variants of concern, including Omicron

31 Dec 2021

The use of monoclonal antibodies against infectious pathogens

Joshua Tan of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health wrote a review article in the journal DNA and Cell Biology about the role of monoclonal antibodies and briefly described a study on bispecific antibodies that neutralize SARS-CoV-2.

30 Dec 2021

Antibody neutralization of SARS-CoV-2 Omicron variant via BNT162b2 vaccine booster dose

New study findings highlight the need for a rapid booster vaccine campaign to prevent COVID-19 caused by the Omicron variant since the neutralization of Omicron by the two-dose BNT162b2 vaccine is not effective in controlling the spread of the infection.

30 Dec 2021

Researchers suggest hybrid convalescent plasma therapy neutralizes the omicron variant

New research suggests convalescent plasma from unvaccinated donors is not effective against the Omicron variant, however, “hybrid” convalescent plasma from donors who recovered from COVID-19 infection and are vaccinated provides considerable antibody protection.

29 Dec 2021

SARS-CoV-2 Omicron variant neutralized by third BNT162b2 booster shot

A new preprint* research paper under consideration at Nature Portfolio Journal assesses the susceptibility of the Omicron variant to neutralizing antibody response after booster immunization.

28 Dec 2021

$Clinical trial shows preliminary efficacy of all-oral regimen for patients with lenalidomide-refractory multiple myeloma$

Clinical trial shows preliminary efficacy of all-oral regimen for patients with lenalidomide-refractory multiple myeloma

Early results from an Alliance for Clinical Trials in Oncology randomized clinical trial of adults with multiple myeloma relapsing on frontline lenalidomide therapy showed that adding ixazomib (Ninlaro®) to pomalidomide and dexamethasone as part of second line therapy extended the length of time patients lived before their disease worsened (progression-free survival) compared with patients who received pomalidomide and dexamethasone.

21 Dec 2021

New study suggests most monoclonal antibody treatments are ineffective against Omicron SARS-CoV-2 variant

The arrival of the Omicron (B.1.1.529) variant has brought into question the effectiveness of current COVID-19 treatments in preventing infection and death. New research published in the preprint bioRxiv* server suggests the efficacy of most monoclonal antibody treatments are ineffective against Omicron.

20 Dec 2021

A test to identify antibody effectiveness against COVID-19 variants

Since the start of the COVID-19 pandemic, variants have begun to emerge. We spoke to Jacob Heggestad about his rapid test that can detect these variants.

20 Dec 2021

Anti-SARS-CoV-2 antibody infusion shown to demonstrate robust immune response following COVID-19 vaccination

A new study expands the understanding of the impact of receiving a prophylactic monoclonal antibody infusion, as well as other variables, on the endogenous immune response to complete COVID-19 immunization.

20 Dec 2021

Monoclonal Antibody News and Research

Further Reading

Researchers create new monoclonal antibody treatment effective against both Delta and Omicron

Serological antibody response to SARS-CoV-2 infection at a population level

LIVE-AIR trial demonstrates efficacy of Lenzilumab for treatment of COVID patients with decreased oxygen saturation

Booster dose elicits cross-reactive humoral immunity against SARS-CoV-2 Delta and Omicron variants

Monoclonal antibody treatment of COVID-19 reduces viral shedding

Folic acid-like drug reprograms DNA methylome of aggressive brain tumors

Efficacy of COVID-19 convalescent plasma therapy in patients with hematological malignancies and COVID-19

Study finds pan-sarbecovirus nanobodies can enhance development of super-immunity

Sino Biological Establishes New Location in Houston, Texas

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

TriSb92 as a potential inhibitor against SARS-CoV-2 variants including Omicron

The use of monoclonal antibodies against infectious pathogens

Antibody neutralization of SARS-CoV-2 Omicron variant via BNT162b2 vaccine booster dose

Researchers suggest hybrid convalescent plasma therapy neutralizes the omicron variant

SARS-CoV-2 Omicron variant neutralized by third BNT162b2 booster shot

Clinical trial shows preliminary efficacy of all-oral regimen for patients with lenalidomide-refractory multiple myeloma

New study suggests most monoclonal antibody treatments are ineffective against Omicron SARS-CoV-2 variant

A test to identify antibody effectiveness against COVID-19 variants

Anti-SARS-CoV-2 antibody infusion shown to demonstrate robust immune response following COVID-19 vaccination

Immunology eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®